Wolverine Trading’s Atea Pharmaceuticals AVIR Stock Holding History

Wolverine Trading’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,800	Closed	-$100K	–	4196
2022 Q4	$100K	Buy	+20,800	New	+$105K	﹤0.01%	3412
2022 Q2	–	Sell	-28,500	Closed	-$202K	–	4478
2022 Q1	$202K	Sell	28,500 -17,200	-38%	-$117K	﹤0.01%	4424
2021 Q4	$414K	Buy	+45,700	New	+$712K	﹤0.01%	3702

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wolverine Trading's AVIR Position: Q3 2025 in Review

Wolverine Trading reduced its Atea Pharmaceuticals (AVIR) stake by 4.7% in Q3 2025, selling an estimated $2.55K and leaving 14,982 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5445.

Wolverine Trading first reported a position in AVIR in Q1 2022 and has held it in 5 quarters since. The position peaked at $85.5K in Q1 2024. 115 funds tracked by Wall St. Rank hold AVIR as of Q3 2025.

Wolverine Trading held 14,982 shares of Atea Pharmaceuticals worth $43.7K as of Q3 2025.
Wolverine Trading sold 747 Atea Pharmaceuticals shares in Q3 2025, an estimated $2.55K.
Atea Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5445 holding.
Wolverine Trading first reported a position in Atea Pharmaceuticals in Q1 2022 and has held it in 5 quarters since.
Wolverine Trading's Atea Pharmaceuticals position peaked at $85.5K in Q1 2024.
115 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.